MBX Biosciences, Inc. Share Price
MBXMBX Biosciences, Inc. Stock Performance
Open $31.21 | Prev. Close $31.43 | Circuit Range N/A |
Day Range $30.93 - $32.26 | Year Range $9.43 - $45.61 | Volume 19,632 |
Average Traded $31.63 |
MBX Biosciences, Inc. Share Price Chart
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX Biosciences, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
21-May-26 | $31.21 | $32.26 | +0.00% |
21-May-26 | $31.21 | $32.26 | +6.24% |
19-May-26 | $30.84 | $30.36 | -2.03% |
18-May-26 | $32.45 | $30.99 | -4.29% |
15-May-26 | $35.19 | $32.38 | -8.35% |
14-May-26 | $36.48 | $35.33 | -5.94% |
13-May-26 | $37.62 | $37.56 | +1.51% |